Alexion makes $1.2B deal to purchase Syntimmune

Sep 26, 2018

Alexion Pharmaceuticals announced this week that it is buying Syntimmune in a deal that could be worth $1.2 billion.

The purchase will include Syntimmune’s portfolio of treatments for rare diseases including SYNT001, a medication that autoimmune hemolytic anemia. The deal is another step in Alexion’s bid to bolster its pipeline for drugs that treat rare disorders and diversify the company’s clinical-stage portfolio.

Alexion also announced that it is buying Wilson Therapeutics for $855 million in April. As part of the deal with Syntimmune, Alexion will make an initial payment of $400 million and then add additional payments worth up to $800 million, pending certain drug development milestones.

Read the full Reuters report.

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments